Company

EndogenX, Inc. based in Los Gatos, California, is engaged in developing, acquiring, and commercializing novel pharmaceutical, therapeutic, and diagnostic products/applications worldwide.

As a drug development company, EndogenX licenses drug candidates as they complete the discovery and early pre-clinical testing phase. These candidates come from many sources including Company sponsored research, and have primarily come from university laboratories. Our focus is to rapidly and cost effectively validate the efficacy and safety of these drugs in humans through clinical trials and general use, prior to seeking an out-license or co-development partner to further develop and to commercialize the drug.

The Company seeks to maintain a well diversified portfolio of drug candidates in its clinical pipeline to minimize its dependence on any one drug or therapeutic category. EndogenX is able to address multiple therapeutic categories through its extensive use of third party consultants, advisors and service providers. Through careful selection of drug candidates and clinical trial locations, the company's products will rapidly reach approval for human use. Focusing on co-formulations of previously approved drugs significantly reduces clinical testing hurdles and duration. Conducting clinical trials in foreign countries such as India can significantly reduce the cost and time for obtaining regulatory approvals. EndogenX has introduced a wound care product and a non-toxic anti-microbial topical solution for retail sale and distribution.